Lab
Eastgene Laboratories INC
Eastgene Laboratories INC was paid $5.01M by Medicaid between Jan 2018 and Dec 2024, across 12 billing codes. Its largest line is 88120, — 25% of everything it billed.
33Billing provider infoEASTGENE LABORATORIES INC
FLUSHING, NY 11358
FLUSHING, NY 11358
33aNPI1740546316assigned 04/07/2012
33bProvider typeClinical Medical Laboratory
28Total paid$5.01M
24GClaims90,863
24DCodes billed12
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#28 of 116
Median peer was paid$618K
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,131 | $78K | |
| 2019 | 5,616 | $247K | |
| 2020 | 4,685 | $331K | |
| 2021 | 32,742 | $1.72M | |
| 2022 | 20,351 | $1.05M | |
| 2023 | 13,367 | $866K | |
| 2024incomplete | 9,971 | $717K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88120 | 25% | 7,624 | 6,596 | $1.25M | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 22% | 17,147 | 14,424 | $1.10M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 16% | 11,578 | 10,380 | $781K |
| 88313 | 10% | 8,281 | 7,443 | $512K | |
| 88312 | 9.3% | 5,941 | 5,928 | $465K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 7.2% | 16,888 | 14,214 | $361K |
| 88342 | 5.1% | 9,608 | 8,249 | $257K | |
| 88112 | 3.0% | 9,206 | 7,285 | $148K | |
| 88121 | 1.7% | 827 | 808 | $86K | |
| 88341 | <1% | 370 | 369 | $27K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,379 | 2,482 | $22K |
| 88300 | 0% | 14 | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQIU, LIBO (PRESIDENT)